CCCWFU 99211: Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Bladder Cancer
Dr. Charles Kuzma
Men or women, ages 18 and older, who are current smokers and have been diagnosed with lung, breast, prostate, colorectal, bladder, head & neck, or cervical cancer. For additional criteria, call the Research Coordinator or visit the study weblink.
Wake Forest University
Continued smoking after a cancer diagnosis has important health consequences beyond the risks associated with smoking in the general population. Smoking reduces the efficacy of cancer treatments including surgery, radiation and chemotherapy. Despite the negative consequences, it is estimated that between 15-75% of patients with cancer continue to smoke after their cancer diagnosis. Lung, breast, prostate, colorectal, bladder, head & neck, and cervical cancer patients were chosen because there is evidence of potential clinical benefit associated with quitting smoking in all of these populations and they represent a mix of both smoking and non-smoking related cancers.